Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

OBJECTIVE: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiographic progression in psoriatic arthritis (PsA). METHODS: We conducted preplanned integrated analyses of combined radiographic data from PSUMMIT-1 and PSUMMIT-2 phase 3, randomised, controlled trials. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanaugh, Arthur, Ritchlin, Christopher, Rahman, Proton, Puig, Lluis, Gottlieb, Alice B, Li, Shu, Wang, Yuhua, Noonan, Lenore, Brodmerkel, Carrie, Song, Michael, Mendelsohn, Alan M, McInnes, Iain B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033146/
https://www.ncbi.nlm.nih.gov/pubmed/24553909
http://dx.doi.org/10.1136/annrheumdis-2013-204741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033146/
https://www.ncbi.nlm.nih.gov/pubmed/24553909
http://dx.doi.org/10.1136/annrheumdis-2013-204741

Ejemplares similares